IP Library › Patent Application 11418137
Patent Application
App. No. 11/418,137

Salts of (-)-O-desmethylvenlafaxine

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/418,137
Abstract

Methods of preparing, and compositions comprising, derivatives of (−)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.

Claims (15)

1 - 60 . (canceled)

61 . Optically pure (−)-O-desmethylvenlafaxine hydrochloride.

62 . Optically pure (−)-O-desmethylvenlafaxine hydrochloride monohydrate.

63 . A pharmaceutical composition comprising optically pure (−)-O-desmethylvenlafaxine hydrochloride and a pharmaceutically acceptable carrier or excipient.

64 . A pharmaceutical composition comprising optically pure (−)-O-desmethylvenlafaxine hydrochloride monohydrate and a pharmaceutically acceptable carrier or excipient.

65 . The pharmaceutical composition of claim 63 or 64 adapted for parenteral or oral delivery.

66 . The pharmaceutical composition of claim 65 , wherein the composition is a solid oral dosage form.

67 . The pharmaceutical composition of claim 66 , wherein the composition is a tablet or capsule.

68 . A single unit dosage form comprising a therapeutically effective amount of optically pure (−)-O-desmethylvenlafaxine hydrochloride and a pharmaceutically acceptable carrier or excipient.

69 . The dosage form of claim 68 , wherein the (−)-O-desmethylvenlafaxine hydrochloride is a monohydrate.

70 . The dosage form of claim 68 adapted for parenteral or oral delivery.

71 . The dosage form of claim 68 , which is a tablet or a capsule.

72 . The dosage form of claim 68 , wherein the therapeutically effective amount is from about 10 mg to about 1000 mg.

73 . The dosage form of claim 72 , wherein the therapeutically effective amount is from about 50 mg to about 500 mg.

74 . The dosage form of claim 73 , wherein the therapeutically effective amount is from about 75 mg to about 350 mg.